Zidovudine |
|
|
|
|
|
Increase |
Positive |
|
307 |
Acyclovir |
|
|
|
|
|
Increase |
Positive |
|
307 |
Ganciclovir |
|
|
|
|
|
Increase |
Positive |
|
307 |
Zalcitabine |
|
|
|
|
|
Increase |
Positive |
|
307 |
amphotericin B |
2.5mg/ml |
|
Aspergillus fumigatus |
|
oxidant-sensing fluorescent probe 2′,7′-dichlorofluorescin diacetate t |
induce |
Positive |
|
304 |
Terbinafine |
4mg/ml |
|
Aspergillus fumigatus |
|
oxidant-sensing fluorescent probe 2′,7′-dichlorofluorescin diacetate t |
induce |
Positive |
|
304 |
itraconazole |
4mg/ml |
|
Aspergillus fumigatus |
|
oxidant-sensing fluorescent probe 2′,7′-dichlorofluorescin diacetate t |
induce |
Positive |
|
304 |
P110 |
1 µM |
2hr |
|
SH-SY5Y cells were treated with P110 (1 µM) followed by incubation of MPP+ (2 mM) for 2 hours. |
Mitochondrial superoxide production was determined using the mitochondrial superoxide indicator MitoSOX Red. Total ROS production was determined in SH-SY5Y cells using CM2-HDCFA. |
reduce |
Positive |
|
310 |
Clofibrate |
|
|
|
|
|
|
Positive |
|
185 |
Amiodarone |
|
|
|
|
|
|
Positive |
|
185 |
neomycin |
50 μM |
|
zebrafish |
zebrafish lateral line hair |
use ROS indicator dye cellROX green ( it labels a number of intracellular compartments, including cytoplasm, nucleus, and mitochondria) |
increase |
Positive |
|
315 |
Staurosporine |
2 µM |
24hr |
|
U2OS |
mt-roGFP and mitoSOX |
increase |
Positive |
|
313 |
camptothecin |
30 µM |
24hr |
|
U2OS |
mt-roGFP and mitoSOX |
increase |
Positive |
|
313 |
Menadione |
20 µM |
24hr |
|
U2OS |
mt-roGFP and mitoSOX |
increase |
Positive |
|
313 |
Cisplatin |
150 µM |
24hr |
|
U2OS |
U2OS cells stably expressing mt-roGFP and HyPer-red targeted at mitochondria |
increase |
Positive |
|
313 |
camptothecin |
30 µM |
24hr |
|
U2OS |
U2OS cells stably expressing mt-roGFP and HyPer-red targeted at mitochondria |
increase |
Positive |
|
313 |
Ciprofloxacin |
|
|
|
|
|
Increase |
Positive |
|
307 |
Mitoquinone |
|
|
|
U2OS |
mt-roGFP ratio change (Quantitative representation of the percentage of cell death in cells pre-treated with MitoQ followed by drug treatment or drug alone as indicated for 24 h) |
reduce |
Positive |
|
313 |
Cisplatin |
|
|
|
|
|
Increase |
Positive |
|
307 |
Cyclophosphamide |
|
|
|
|
|
Increase |
Positive |
|
307 |
Gentamicin |
5mM |
10min |
rat |
isolated rat liver (and kidney) mitochondria |
Mitochondrial ROS production can be measured using Amplex Red, a dye that fluoresces dependent on hydrogen peroxide (H2O2) levels. |
reduce |
Positive |
|
316 |
glyceraldehyde 3-phosphate |
2.5mM |
|
|
|
|
decrease |
Positive |
|
162 |
dihydroxyacetone phosphate |
|
|
|
|
|
decrease |
Positive |
|
162 |
Berberine |
25 μM |
6, 24 hr |
|
K1735-M2 mouse melanoma cells |
CM-H2DCFDA (DCF), a fluorescent probe for oxidative stress (epifluorescence microscope) |
increase |
Positive |
|
327 |
Acetaminophen |
|
|
|
|
|
increase |
Positive |
|
35 |
Menadione |
|
|
|
|
|
increase |
Positive |
|
35 |
Troglitazone |
|
|
human |
hepatocytes |
cell viability assay |
|
Positive |
|
226 |
CGP37157 |
1 μmol/L |
|
rat |
ventricular myocytes |
redox-sensitive OMM-HyPer and ERroGFP_iE biosensors |
|
Positive |
|
241 |
kaempferol |
10 μmol/L |
|
rat |
ventricular myocytes |
redox-sensitive OMM-HyPer and ERroGFP_iE biosensors |
|
Positive |
|
241 |
MitoTEMPO |
20 μmol/L |
|
|
|
|
|
Positive |
|
241 |
Amiodarone |
1 μmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
p < 0.05 |
4 |
Amiodarone |
100 μmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
p < 0.05 |
4 |
benzarone |
10 μmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
started to be detectable |
4 |
benzarone |
100 μmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
p < 0.01 |
4 |
benzbromarone |
0.1 nmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
started to be detectable |
4 |
benzbromarone |
0.1 μmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
p < 0.05 |
4 |
benzbromarone |
1 μmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
p < 0.01 |
4 |
benzbromarone |
100 μmol/L |
1 hour |
human |
HepG2 |
Measurement of ROS |
increase |
Positive |
p < 0.01 |
4 |
Sulindac |
|
|
|
|
|
increase |
Positive |
|
45 |
Diflunisal |
558 |
|
rat |
hepatocytes |
use CM-H2DCFDA to monitor reactive oxygen species |
|
Positive |
AC50 (μM) |
40 |
Sulindac sulfide |
109 |
|
rat |
hepatocytes |
use CM-H2DCFDA to monitor reactive oxygen species |
|
Positive |
AC50 (μM) |
40 |
Nimesulide |
574 |
|
rat |
hepatocytes |
use CM-H2DCFDA to monitor reactive oxygen species |
|
Positive |
AC50 (μM) |
40 |
Acetaminophen |
|
|
|
|
|
|
Positive |
|
243 |
Acetylcysteine |
|
|
|
|
rho-GFP (Redox-sensitive GFP) |
|
Positive |
|
244 |
Amitriptyline |
|
|
|
|
|
|
Positive |
|
197 |
Desipramine |
|
|
|
|
|
|
Positive |
|
197 |
Valproic Acid |
|
|
|
|
|
increase |
Positive |
|
197 |
Doxorubicin |
|
|
|
|
|
increase |
Positive |
|
197 |
Efavirenz |
|
|
|
|
|
increase |
Positive |
|
197 |
Propofol |
|
|
|
|
|
increase |
Positive |
|
197 |
Ketamine |
|
|
|
|
|
increase |
Positive |
|
197 |
Paraquat |
10 mg/kg/week intraperitoneal (i.p.) |
4 weeks |
C57BL/6 mice |
|
|
|
Positive |
|
242 |
Paraquat |
250 μM |
5min |
Sprague Dawley rat |
brain cultures |
|
|
Positive |
|
242 |
Rotenone |
0.1–0.5 nmol/mg protein |
|
Wistar rat |
brain isolated mitochondria |
|
increase |
Positive |
|
242 |
Manganese |
0.1–10 μM |
|
|
Sprague Dawley rat astrocytes and microglia cell culture |
|
reduce |
Positive |
|
242 |
Manganese |
15 mg/l in drinking water |
|
Swiss Albino mice |
|
|
increase |
Positive |
|
242 |
Aluminium |
10 mg/kg/day intragastric for 12 weeks |
|
Wistar rats |
|
|
|
Positive |
|
242 |
Methylmercury |
15 mg/l in drinking water |
|
Swiss albino mice |
|
|
|
Positive |
|
242 |
Ethanol |
|
|
rat |
liver |
|
|
Positive |
|
259 |
Acetaminophen |
|
|
|
|
|
|
Positive |
|
258 |
Doxorubicin |
|
|
|
|
|
|
Positive |
|
250 |
Etomoxir |
5 μM |
|
|
T cell |
|
|
Positive |
|
257 |
Ubidecarenone |
|
|
|
|
|
|
Positive |
|
248 |
Mitoquinone |
|
|
|
|
|
|
Positive |
|
248 |
Acetaminophen |
300 mg/kg |
3 hours |
mice; C57Bl/6 |
in vivo |
ALT activity measurement |
increase |
Positive |
p < 0.05 |
1 |
Acetaminophen |
300 mg/kg |
6 hours |
mice; C57Bl/6 |
in vivo |
ALT activity measurement |
increase |
Positive |
p < 0.05 |
1 |
Cadmium |
50, 100 μM |
|
|
HPNE cell (human pancreatic Nestin-expressing cells) |
oxidative stress was assessed by measuring DCF fluorescence |
increase |
Positive |
|
334 |
Cadmium |
50, 100 μM |
|
|
AsPC-1 cells (pancreatic tumor cells) |
oxidative stress was assessed by measuring DCF fluorescence |
increase |
Positive |
|
334 |
Acetaminophen |
1.5 g/kg |
24 hours |
rat; Fischer (F344) |
in vivo |
ALT activity measurement |
increase |
Positive |
p < 0.05 |
1 |
Acetaminophen |
300 mg/kg |
24 hours |
mice; C57Bl/6 |
in vivo |
ALT activity measurement |
increase |
Positive |
p < 0.05 |
1 |
Acetylsalicylic acid |
10 μmol/ml |
24 hours |
human |
HepG2 |
ROS measurement |
increase |
Positive |
p < 0.05 |
2 |
Acetylsalicylic acid |
10 μmol/ml |
48 hours |
human |
HepG2 |
ROS measurement |
increase |
Positive |
p < 0.05 |
2 |
Nimesulide |
1 mM |
|
rat; Sprague-Dawley Crl:CD (SD) BR |
lung microsomes |
adrenochrome assay (Misra and Fridovich, 1972) |
increase |
Positive |
p < 0.05 |
11 |
Nimesulide |
0.5 mM |
20 minutes |
rat; Sprague-Dawley Crl:CD (SD) BR |
lung microsomes |
horseadish preoxidase method (Green and Hill, 1984) |
increase |
Positive |
p < 0.05 |
11 |
Rotenone |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
tacrolimus |
50 µg/ml |
12hr |
|
INS-1 cells |
MitoSOX Red staining to detect mitochondrial superoxide anion (O2−) levels by flow cytometric analysis and e time-lapse images of cells treated for 12 h with MitoSOX Red. |
induce |
Positive |
|
322 |
Paraquat |
10 mM |
|
yeast; EG110 (MnSOD knock-out) |
mitochondria |
Measurement of superoxide anion; Used ethanol (5 mM) as substrate |
increase |
Positive |
|
14 |
Paraquat |
10 mM |
|
yeast; EG103 (Wild-type) |
mitochondria |
Measurement of superoxide anion; Used ethanol (5 mM) as substrate |
increase |
Positive |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of superoxide anion; Used glutamate/malate (5 mM) as substrate |
increase |
Positive |
|
14 |
Paraquat |
0.1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of superoxide anion; Used succinate (5 mM) as substrate |
increase |
Positive |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of hydrogen peroxide; Used glutamate/malate (5 mM) as substrate |
increase |
Positive |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of hydrogen peroxide; Used succinate (5 mM) as substrate |
increase |
Positive |
|
14 |
MG-132 |
20 μM |
24 hr |
rat |
PC12 cells |
Measurement of intracellular ROS formation with DCFH2-DA |
increase |
Positive |
|
289 |
3-morpholinosydnonimine |
150 μM |
24 hr |
rat |
PC12 cells |
Measurement of intracellular ROS formation with DCFH2-DA |
decrease |
Positive |
|
289 |
Cisplatin |
84.96 ± 3, 158.9 ± 8.2, 372.7 ± 17.5 and 499.5 ± 15.1 μM |
24 hr |
|
Ishikawa, MDA-MB-231, PC-3 and Caco-2 |
Intracellular ROS (a) and mitochondrial superoxide were measured by fluorescence intensity of H2DCFDA and MitoSOX respectively. |
increase |
Positive |
IC50 |
299 |
Dequalinium Chloride |
14.24 ± 0.59, 57.85 ± 3.59, 93.31 ± 3.21 and 179.2 ± 5.2 μM |
24 hr |
|
Ishikawa, MDA-MB-231, PC-3 and Caco-2 |
Intracellular ROS (a) and mitochondrial superoxide were measured by fluorescence intensity of H2DCFDA and MitoSOX respectively. |
increase |
Positive |
IC50 |
299 |
Metformin |
1 mM |
24 hours |
human |
hepatocytes |
ROS measurement |
increase |
Positive |
|
15 |
Metformin |
2 mM |
24 hours |
human |
hepatocytes |
ROS measurement |
increase |
Positive |
|
15 |
buformin |
75 μM |
24 hours |
human |
hepatocytes |
ROS measurement |
increase |
Positive |
|
15 |
Phenformin |
12.5 μM |
24 hours |
human |
hepatocytes |
ROS measurement |
increase |
Positive |
|
15 |
Amiodarone |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Chlorpromazine |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Cyclosporin A |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
imipramine |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Maprotiline |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Metformin |
1 mM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
affect |
Positive |
|
15 |
Metformin |
2 mM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
affect |
Positive |
|
15 |
buformin |
75 μM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
affect |
Positive |
|
15 |
Phenformin |
12.5 μM |
24 hours |
human |
hepatocytes |
Measurement of mitochondrial membrane potential |
affect |
Positive |
|
15 |
Tamoxifen |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Troglitazone |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
atorvastatin |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Cerivastatin |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
fluvastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
lovastatin |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
pravastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |
Simvastatin |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Increase |
Positive |
MEC |
306 |